Open AccessThe monoclonal antibody to cytotoxic T lymphocyte antigen 4, ipilimumab, in the treatment of melanoma
Author(s) -
Claire F. Verschraegen
Publication year - 2012
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s15551
Subject(s) - ipilimumab , medicine , monoclonal antibody , melanoma , immunology , immune system , ctla 4 , antigen , immunotherapy , cytotoxic t cell , antibody , adverse effect , clinical trial , oncology , t cell , cancer research , biology , in vitro , biochemistry
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is an inhibitory regulator of the T-cell immune response against tumor cells. Ipilimumab is a monoclonal antibody directed against CTLA-4.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom